Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104796 | 0.85 | CHRNA7 (0.51) | PTGS2ALOX5PTGS1CHRNA7CA9 | |
| SCHEMBL3098478 | 0.85 | CHRNA7 (0.51) | PTGS2PTGS1CHRNA7CA9CA1 | |
| SCHEMBL3101600 | 0.83 | CA9 (0.72) | PTGS2CHRNA7CA9CA1CA2 | |
| SCHEMBL5430032 | 0.82 | CA9 (0.74) | PTGS2ALOX5PTGS1CHRNA7CA9 | |
| SCHEMBL3109266 | 0.82 | PTGS2 (0.52) | PTGS2PTGS1CHRNA7CA9CA1 | |
| SCHEMBL3112808 | 0.81 | PTGS2 (0.46) | PTGS2ALOX5PTGS1CHRNA7CA9 | |
| SCHEMBL5698738 | 0.80 | PTGS2 (0.65) | PTGS2ALOX5PTGS1CA9CA1 | |
| SCHEMBL1259296 | 0.80 | ALDH1A1 (0.64) | KMT2A | |
| SCHEMBL3102280 | 0.80 | PTGS2 (0.63) | PTGS2PTGS1CA9CA1CA2 | |
| SCHEMBL5236666 | 0.80 | RPA1 (0.72) | PTGS2ALOX5PTGS1CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | PTGS2 47/4885ALOX5 1987/4885PTGS1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.